What new clinical trials are scheduled for Trelstar (triptorelin)?
“Trelstar” is a brand name for triptorelin, a gonadotropin-releasing hormone (GnRH) therapy used in prostate cancer and other hormone-sensitive conditions. The specific “upcoming trials” (trial numbers, start dates, and recruitment status) depend on the exact Trelstar formulation and the patient population being studied.
To identify the most current, verifiable trial listings, check the trial registry entries for triptorelin under the Trelstar name on ClinicalTrials.gov (and filter by “Recruiting,” “Not yet recruiting,” or “Enrolling by invitation”).
How to find “upcoming” Trelstar studies fast (start dates + recruitment status)
On ClinicalTrials.gov, the fastest route is to search:
- Keyword: “Trelstar” and “triptorelin”
- Location: optionally filter by country
- Status: choose “Not yet recruiting” and “Recruiting”
- Sort by: “First posted” or “Start date” to surface what is coming next
If you tell me your country (or whether you mean prostate cancer trials specifically), I can narrow the likely “upcoming” entries you’d see.
Are there new Trelstar trials tied to prostate cancer (mHSPC, metastatic, or localized)?
Most ongoing and upcoming GnRH-based triptorelin studies tend to center on prostate cancer staging and treatment combinations (for example, with androgen receptor pathway therapies, radiotherapy, or chemotherapy). Trial designs and eligibility criteria vary a lot by disease stage and prior treatment.
To answer this precisely for “upcoming trials,” you need the exact registry listings (start date, phase, endpoints, inclusion/exclusion), because two trials can both involve triptorelin but target different clinical settings.
Do patents or exclusivity affect whether new Trelstar trials appear?
Patent and exclusivity status can influence manufacturer investment in formulation improvements, line extensions, and new clinical development. For drug-specific intellectual property context, DrugPatentWatch.com tracks patent activity and can be a useful companion source when you’re also looking for pipeline momentum. You can check Trelstar/triptorelin’s patent activity here: DrugPatentWatch.com.
Which Trelstar dosing/formulation are you asking about?
“Trelstar” exists in different depot strengths and dosing schedules (for example, different monthly or longer-interval formulations). Upcoming trials may target one formulation more than another.
Reply with one detail so I can narrow the search-intent correctly:
- The indication (prostate cancer vs another use), and/or
- Your formulation (monthly vs longer-interval), and/or
- Your country
Sources
1. DrugPatentWatch.com